Treats obsessions and compulsions. ANDA 74694, held by Taro. Clomipramine Hydrochloride.
As of Nov 16, 2026, ANDA 74694 (Clomipramine Hydrochloride), held by Taro, was first approved by FDA on Dec 31, 1996, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 1996 | Original application | Approved | None posted |
| Clomipramine Hydrochloride25MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride50MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Clomipramine Hydrochloride75MG · capsule;oral | Clomipramine Hydrochloride | Rx |
| Jan 28, 2026 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 30, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 30, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 20, 2008 | Supplement 5Labeling | Approved | None posted |
| Jun 29, 2007 | Supplement 4Labeling | Approved | None posted |
| Apr 20, 2005 | Supplement 2Labeling | Approved | None posted |
| Sep 14, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Dec 31, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters